Health knowledge made personal
Join this community!
› Share page:
Search posts:

Improved Monoclonal Antibodies Against Neuregulin 2

Posted Nov 05 2012 7:00pm

Description of Invention:
The invention provides highly selective monoclonal antibodies against the extracellular domain (ECD) or intracellular domain (ICD) of neuregulin-2, a ligand for the ErbB receptors in adult human brain. Neuregulins regulate a diverse array of neurological process in the central nervous system and are implicated in schizophrenia and other psychiatric disorders. However, an understanding of the specific role of neuregulin 2 has been hindered by a lack of specific antibodies useful in immunoblotting and immunohistology studies. Commercially available antibodies do not perform as well in these applications when compared to the invention antibodies. A mouse monoclonal antibody directed to the ECD is available for licensing (clone 8D11, HHS Ref. No. E-192-2012), and rabbit antibodies directed to the ICD are also available (clone 11-11, HHS Ref. No. E-193-2012; clone 15-10, HHS Ref. No. E-189-2012; and clone 9-2, HHS Ref. No. E-188-2012). Antibodies from clones 8D11 and 11-11 have been validated for immunohistology and antibodies from clones 15-10 and 9-2 have been validated for Western blotting using brain tissue from wild-type and neuregulin 2 deficient mice.

Superior monoclonal antibody for Western blotting or immunohistology analysis of tissue sections

  • Superior binding specificity in comparison to commercially available antibodies
  • Developed antibodies bind specific, characterized regions on neuregulin 2

Development Status:
  • Prototype
  • In vitro data available

Detlef Vullhorst (NICHD)
Andres L Buonanno (NICHD)
Irina D Karavanov (NICHD)

Patent Status:
HHS, Reference No. E-188-2012/0
HHS, Reference No. E-189-2012/0
HHS, Reference No. E-190-2012/0
HHS, Reference No. E-191-2012/0
HHS, Reference No. E-192-2012/0
HHS, Reference No. E-193-2012/0

This is a Research Tool — patent protection is not being pursued for this technology.

Collaborative Research Opportunity:
The NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize neuregulin-2 monoclonal antibodies. For collaboration opportunities, please contact Charlotte McGuinness at .

For Licensing Information Please Contact:
Lauren Nguyen-Antczak Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-496-7057
Fax: 301-402-0220

Ref No: 2492

Updated: 11/2012

Post a comment
Write a comment:

Related Searches